Ablation is a minimally invasive procedure to treat abnormal electrical short circuits caused by a heart attack. These ...

From its cardiovascular divisions, Medtronic brought in $3.1 billion for an increase of 6.1%—driven in part by the launches ...

CEO Geoff Martha said the business did not meet internal growth expectations last quarter due to third-party supply issues ...

With supplier issue now resolved, the Minnesota-run medtech company expects to “reach and then exceed” market growth in the ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Diabetes shines, cardiac ablation stumbles, and new products spark hope--Medtronic's Q2 FY25 shakes up expectations.

There is no credible evidence supporting false claims that listening to soundwaves of a specific frequency can safely "kill ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

Medtronic — the world's largest medical device company — is preparing for potential new import taxes and other policy changes ...

Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.

Medtronic is raising its full-year guidance following second-quarter results that came in ahead of the consensus forecast.

Medtronic (NYSE: MDT) Q2 2025 Earnings Call Nov 19, 2024, 8:00 a.m. ET ...